title: Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
abstract: BACKGROUND
  Most persons who are infected with human immunodeficiency virus type 1 (HIV-1) are also infected with herpes simplex virus type 2 (HSV-2), which is frequently reactivated and is associated with increased plasma and genital levels of HIV-1. Therapy to suppress HSV-2 reduces the frequency of reactivation of HSV-2 as well as HIV-1 levels, suggesting that suppression of HSV-2 may reduce the risk of transmission of HIV-1.
  
  
  METHODS
  We conducted a randomized, placebo-controlled trial of suppressive therapy for HSV-2 (acyclovir at a dose of 400 mg orally twice daily) in couples in which only one of the partners was seropositive for HIV-1 (CD4 count, > or = 250 cells per cubic millimeter) and that partner was also infected with HSV-2 and was not taking antiretroviral therapy at the time of enrollment. The primary end point was transmission of HIV-1 to the partner who was not initially infected with HIV-1; linkage of transmissions was assessed by means of genetic sequencing of viruses.
  
  
  RESULTS
  A total of 3408 couples were enrolled at 14 sites in Africa. Of the partners who were infected with HIV-1, 68% were women, and the baseline median CD4 count was 462 cells per cubic millimeter. Of 132 HIV-1 seroconversions that occurred after randomization (an incidence of 2.7 per 100 person-years), 84 were linked within couples by viral sequencing: 41 in the acyclovir group and 43 in the placebo group (hazard ratio with acyclovir, 0.92, 95% confidence interval [CI], 0.60 to 1.41; P=0.69). Suppression with acyclovir reduced the mean plasma concentration of HIV-1 by 0.25 log(10) copies per milliliter (95% CI, 0.22 to 0.29; P<0.001) and the occurrence of HSV-2-positive genital ulcers by 73% (risk ratio, 0.27; 95% CI, 0.20 to 0.36; P<0.001). A total of 92% of the partners infected with HIV-1 and 84% of the partners not infected with HIV-1 remained in the study for 24 months. The level of adherence to the dispensed study drug was 96%. No serious adverse events related to acyclovir were observed.
  
  
  CONCLUSIONS
  Daily acyclovir therapy did not reduce the risk of transmission of HIV-1, despite a reduction in plasma HIV-1 RNA of 0.25 log(10) copies per milliliter and a 73% reduction in the occurrence of genital ulcers due to HSV-2. (ClinicalTrials.gov number, NCT00194519.)
authors.affiliation: Department of Global Health, University of Washington, Harborview Medical Center, 325 Ninth Ave., Box 359927, Seattle, WA 98104, USA.
authors.forename: C
authors.initials: C
authors.lastname: Celum
authors.forename: A
authors.initials: A
authors.lastname: Wald
authors.forename: J R
authors.initials: JR
authors.lastname: Lingappa
authors.forename: A S
authors.initials: AS
authors.lastname: Magaret
authors.forename: R S
authors.initials: RS
authors.lastname: Wang
authors.forename: N
authors.initials: N
authors.lastname: Mugo
authors.forename: A
authors.initials: A
authors.lastname: Mujugira
authors.forename: J M
authors.initials: JM
authors.lastname: Baeten
authors.forename: J I
authors.initials: JI
authors.lastname: Mullins
authors.forename: J P
authors.initials: JP
authors.lastname: Hughes
authors.forename: E A
authors.initials: EA
authors.lastname: Bukusi
authors.forename: C R
authors.initials: CR
authors.lastname: Cohen
authors.forename: E
authors.initials: E
authors.lastname: Katabira
authors.forename: A
authors.initials: A
authors.lastname: Ronald
authors.forename: J
authors.initials: J
authors.lastname: Kiarie
authors.forename: C
authors.initials: C
authors.lastname: Farquhar
authors.forename: G J
authors.initials: GJ
authors.lastname: Stewart
authors.forename: J
authors.initials: J
authors.lastname: Makhema
authors.forename: M
authors.initials: M
authors.lastname: Essex
authors.forename: E
authors.initials: E
authors.lastname: Were
authors.forename: K H
authors.initials: KH
authors.lastname: Fife
authors.forename: G
authors.initials: G
authors.lastname: de Bruyn
authors.forename: G E
authors.initials: GE
authors.lastname: Gray
authors.forename: J A
authors.initials: JA
authors.lastname: McIntyre
authors.forename: R
authors.initials: R
authors.lastname: Manongi
authors.forename: S
authors.initials: S
authors.lastname: Kapiga
authors.forename: D
authors.initials: D
authors.lastname: Coetzee
authors.forename: S
authors.initials: S
authors.lastname: Allen
authors.forename: M
authors.initials: M
authors.lastname: Inambao
authors.forename: K
authors.initials: K
authors.lastname: Kayitenkore
authors.forename: E
authors.initials: E
authors.lastname: Karita
authors.forename: W
authors.initials: W
authors.lastname: Kanweka
authors.forename: S
authors.initials: S
authors.lastname: Delany
authors.forename: H
authors.initials: H
authors.lastname: Rees
authors.forename: B
authors.initials: B
authors.lastname: Vwalika
authors.forename: W
authors.initials: W
authors.lastname: Stevens
authors.forename: M S
authors.initials: MS
authors.lastname: Campbell
authors.forename: K K
authors.initials: KK
authors.lastname: Thomas
authors.forename: R W
authors.initials: RW
authors.lastname: Coombs
authors.forename: R
authors.initials: R
authors.lastname: Morrow
authors.forename: W L H
authors.initials: WL
authors.lastname: Whittington
authors.forename: M J
authors.initials: MJ
authors.lastname: McElrath
authors.forename: L
authors.initials: L
authors.lastname: Barnes
authors.forename: R
authors.initials: R
authors.lastname: Ridzon
authors.forename: L
authors.initials: L
authors.lastname: Corey
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000212:Acyclovir / Q000009:adverse effects / Q000627:therapeutic use*; D000293:Adolescent; D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000150:complications / Q000635:transmission*; D015497:HIV-1 / Q000235:genetics / Q000302:isolation & purification; D006558:Herpes Genitalis / Q000150:complications / Q000188:drug therapy*; D018258:Herpesvirus 2, Human; D006801:Humans; D057194:Intention to Treat Analysis; D053208:Kaplan-Meier Estimate; D008297:Male; D010349:Patient Compliance; D011247:Pregnancy; D012367:RNA, Viral / Q000097:blood; D047568:Unsafe Sex / Q000706:statistics & numerical data; D055815:Young Adult
chemical_list: D000998:Antiviral Agents; D012367:RNA, Viral; D000212:Acyclovir